Completed PHASE1 INTERVENTIONAL 5-arm NCT00744146

First Time in Human Study of Protexia

Phase I, Randomized, Controlled, Third-party Double-blind, Dose Escalating Study of Protexia Administered Intramuscularly at One or Two Time Points in Healthy Human Volunteers

Sponsor: PharmAthene, Inc.

Conditions Intervention for Nerve Agent Exposure

Interventions Protexia

Updated 7 times since 2017 Last updated: Sep 16, 2010 Started: Sep 30, 2008 Primary completion: Jul 31, 2009 Completion: Nov 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00744146, this PHASE1 trial focuses on Intervention for Nerve Agent Exposure and remains completed. Sponsored by PharmAthene, Inc., it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Feb 2023 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Feb 2023 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PharmAthene, Inc.
QPS Holdings LLC
Quintiles, Inc.
United States Department of Defense

Data source: PharmAthene, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Overland Park, United States